FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 324-331

  Corneli, Amy L ^a   Deese, Jennifer ^a   Wang, Meng ^b   Taylor, Doug ^b   Ahmed, Khatija ^c   Agot, Kawango ^d   Lombaard, Johan ^e   Manongi, Rachel ^f   Kapiga, Saidi ^f   Kashuba, Angela ^g   Van Damme, Lut ^a,h   Agingu, Walter ^a   Ambia, Julie ^a   Asewe, Jesse ^a   De Baetselier, Irith ^a   Chetty Tulsee, Savi ^a   Chiduo, Sarah ^a   Crucitti, Tania ^a   Fransen, Katrien ^a   Gaddiel, John Gardner ^a   Kiernan, Haddie ^a   Kirkendale, Stella ^a   Lalbahadur, Tharnija ^a   Lanham, Michele ^a   Lucky, Temu ^a   Mak'Oketch, Paul ^a   Makatu, Shumani ^a   Malahleha, Mookho ^a   Mandala, Justin ^a   Mankalimeng, Makanda ^a   Masaki, Martha ^a   Mastro, Timothy ^a   McKenna, Kevin ^a   Monedi, Modie Constance ^a   Mullins, Sarah ^a   Nanda, Kavita ^a   Odhiambo, Jacob ^a   Olango, Immaculate ^a   Omullo, Paul ^a   Omungo, Zablon ^a   Owino, Fred ^a   Parker, Caleb ^a   Ratlhagana, Malebo ^a   Reblin, Ilse ^a   Saylor, Lisa ^a   Siguntu, Phumzile ^a   Skhosana, Joseph Short ^a   Troxler, Amanda ^a   Veena, Valentine ^a   Venkatasubramanian, Lalitha ^a   Venter, Gustav ^a   Wong, Christina ^a   more..

^a Department of Social and Behavioral Health Sciences ^*

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c Setshaba Research Centre   (South Africa)

^d IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^e JOSHA Research   (South Africa)

^f KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^g UNC Hamner Institute for Drug Safety Sciences   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Adherence; Africa; FEM PrEP; Pre exposure prophylaxis; Women

Indexed keywords

ORAL CONTRACEPTIVE AGENT; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELL LEVEL; COLOR; CONDOM USE; DRUG BLOOD LEVEL; EDUCATIONAL STATUS; FEMALE; HEALTH BELIEF; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PILL; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; TASTE; UNSAFE SEX; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; HIV INFECTIONS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADENINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; EMTRICITABINE; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ORGANOPHOSPHONATES; RISK FACTORS; TENOFOVIR; YOUNG ADULT;

EID: 84918803609     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000158     Document Type: Article

References (13)

1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2013;381:2083-2090.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
6. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003) [26LB]. Paper presented at: The 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.
7. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.
8. Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143-2155.
9. FHI360. Press release: FHI to initiate orderly closure of FEM-PrEP. 2011. Available at: www.fhi360.org/fhi-statement-fem-prep-hivpreventionstudy, Accessed May 7, 2014.
10. Taylor D, Amico KR, Brown E. Asking about and measuring adherence. Paper presented at: The International Microbicides Conference; April 15-18, 2012; Sydney, Australia.
11. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
12. Adams JL, Sykes C, Menezes P, et al. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr. 2013;62:260-266.
13. Taylor D. The contraceptive use requirement and related findings in the FEM-PrEP trial: were existing contraceptive users more adherent to protocol? Paper presented at: The International Microbicides Conference; April 15-18, 2012; Sydney, Australia.